AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 288: E486-E492, 2005. First published October 26, 2004; doi:10.1152/ajpendo.00196.2004
0193-1849/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/3/E486    most recent
00196.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Granado, M.
Right arrow Articles by López-Calderón, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granado, M.
Right arrow Articles by López-Calderón, A.

Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats

Miriam Granado,1 Teresa Priego,1 Ana I. Martín,2 M. Ángeles Villanúa,1 and Asunción López-Calderón1

1Departamento Fisiología, Facultad de Medicina, Universidad Complutense, Madrid; and 2Departamento Ciencias Morfológicas y Fisiología, Universidad Europea, Madrid, Spain

Submitted 3 May 2004 ; accepted in final form 21 October 2004

Chronic arthritis induces hypermetabolism and cachexia. Ghrelin is a gastrointestinal hormone that has been proposed as a treatment to prevent cachexia. The aim of this work was to examine the effect of administration of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) to arthritic rats. Male Wistar rats were injected with Freund’s adjuvant, and 15 days later arthritic and control rats were daily injected with GHRP-2 (100 µg/kg) or with saline for 8 days. Arthritis induced an increase in serum ghrelin (P < 0.01) and a decrease in serum concentrations of leptin (P < 0.01), whereas GHRP-2 administration increased serum concentrations of leptin. GHRP-2 increased food intake in control rats but not in arthritic rats. However, in arthritic rats GHRP-2 administration ameliorated the external symptoms of arthritis, as it decreased the arthritis score (10.4 ± 0.8 vs. 13.42 ± 0.47, P < 0.01) and the paw volume. In addition, circulating IL-6 and nitrites/nitrates were increased by arthritis, and GHRP-2 treatment decreased the serum IL-6 levels (P < 0.01). To elucidate whether GHRP-2 is able to modulate IL-6 release directly on immune cells, peritoneal macrophage cultures were incubated with GHRP-2 or ghrelin, the endogenous ligand of the growth hormone (GH) secretagogue receptor. Both GHRP-2 (10–7 M) and ghrelin (10–7 M) prevented endotoxin-induced IL-6 and decreased nitrite/nitrate release from peritoneal macrophages in vitro. These data suggest that GHRP-2 administration has an anti-inflammatory effect in arthritic rats that seems to be mediated by ghrelin receptors directly on immune cells.

interleukin-6; inflammation



Address for reprint requests and other correspondence: A. López-Calderón, Dpt Fisiología, Fac Medicina, Univ Complutense, 28040 Madrid, Spain (E-mail: ALC{at}med.ucm.es)




This article has been cited by other articles:


Home page
J EndocrinolHome page
A I Martin, E Castillero, M Granado, M Lopez-Menduina, M A Villanua, and A Lopez-Calderon
Adipose tissue loss in adjuvant arthritis is associated with a decrease in lipogenesis, but not with an increase in lipolysis
J. Endocrinol., April 1, 2008; 197(1): 111 - 119.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
L. D Madison, J. M Scarlett, P. Levasseur, X. Zhu, K. Newcomb, A. Batra, D. Bowe, and D. L Marks
Prostacyclin signaling regulates circulating ghrelin during acute inflammation
J. Endocrinol., February 1, 2008; 196(2): 263 - 273.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Granado, A. I. Martin, M. Lopez-Menduina, A. Lopez-Calderon, and M. A. Villanua
GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia
Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E131 - E141.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
E. Gonzalez-Rey, A. Chorny, G. Robledo, and M. Delgado
Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia
J. Exp. Med., March 20, 2006; 203(3): 563 - 571.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
M Peracchi, M T Bardella, F Caprioli, S Massironi, D Conte, L Valenti, C Ronchi, P Beck-Peccoz, M Arosio, and L Piodi
Circulating ghrelin levels in patients with inflammatory bowel disease
Gut, March 1, 2006; 55(3): 432 - 433.
[Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Granado, T. Priego, A. I. Martin, M{a} A. Villanua, and A. Lopez-Calderon
Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle
Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1007 - E1014.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.